WHO ICTRP trial
Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg…
EUCTR2005-001026-89-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2005-001026-89-DE |
|---|---|
| Public title | Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study) |
| Scientific title | Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study) |
| Primary sponsor | Serono GmbH |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Germany |
| Conditions | Relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS) with relapses MedDRA version: 7.1 Level: LLT Classification code 10028245 |
| Interventions | Trade Name: Rebif Product Name: Rebif 8,8 µg, Rebif 22µg Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1 a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 8,8 or 22… |
| Registration date | May 13, 2005 |
| Target size | 100 |
| Secondary IDs | 25874 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: